Literature DB >> 25266336

The cell death response to enteropathogenic Escherichia coli infection.

Tania Wong Fok Lung1, Jaclyn S Pearson, Ralf Schuelein, Elizabeth L Hartland.   

Abstract

Given the critical roles of inflammation and programmed cell death in fighting infection, it is not surprising that many bacterial pathogens have evolved strategies to inactivate these defences. The causative agent of infant diarrhoea, enteropathogenic Escherichia coli (EPEC), is an extracellular, intestinal pathogen that blocks both inflammation and programmed cell death. EPEC attaches to enterocytes, remains in the gut lumen and utilizes a type III secretion system (T3SS) to inject multiple virulence effector proteins directly into the infected cell, many of which subvert host antimicrobial processes through the disruption of signalling pathways. Recently, T3SS effector proteins from EPEC have been identified that inhibit death receptor-induced apoptosis. Here we review the mechanisms used by EPEC T3SS effectors to manipulate apoptosis and promote host cell survival and discuss the role of these activities during infection.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25266336     DOI: 10.1111/cmi.12371

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  9 in total

1.  Distinct Roles of the Antiapoptotic Effectors NleB and NleF from Enteropathogenic Escherichia coli.

Authors:  Georgina L Pollock; Clare V L Oates; Cristina Giogha; Tania Wong Fok Lung; Sze Ying Ong; Jaclyn S Pearson; Elizabeth L Hartland
Journal:  Infect Immun       Date:  2017-03-23       Impact factor: 3.441

Review 2.  Reprogramming of Cell Death Pathways by Bacterial Effectors as a Widespread Virulence Strategy.

Authors:  Joseph J Wanford; Abderrahman Hachani; Charlotte Odendall
Journal:  Infect Immun       Date:  2022-04-25       Impact factor: 3.609

3.  Engineering the Controlled Assembly of Filamentous Injectisomes in E. coli K-12 for Protein Translocation into Mammalian Cells.

Authors:  David Ruano-Gallego; Beatriz Álvarez; Luis Ángel Fernández
Journal:  ACS Synth Biol       Date:  2015-06-12       Impact factor: 5.110

4.  EspC, an Autotransporter Protein Secreted by Enteropathogenic Escherichia coli, Causes Apoptosis and Necrosis through Caspase and Calpain Activation, Including Direct Procaspase-3 Cleavage.

Authors:  Antonio Serapio-Palacios; Fernando Navarro-Garcia
Journal:  MBio       Date:  2016-06-21       Impact factor: 7.867

Review 5.  Bacterial Control of Pores Induced by the Type III Secretion System: Mind the Gap.

Authors:  Julie Guignot; Guy Tran Van Nhieu
Journal:  Front Immunol       Date:  2016-03-09       Impact factor: 7.561

6.  Attaching and effacing (A/E) lesion formation by enteropathogenic E. coli on human intestinal mucosa is dependent on non-LEE effectors.

Authors:  Massiel Cepeda-Molero; Cedric N Berger; Alistair D S Walsham; Samuel J Ellis; Simon Wemyss-Holden; Stephanie Schüller; Gad Frankel; Luis Ángel Fernández
Journal:  PLoS Pathog       Date:  2017-10-30       Impact factor: 6.823

7.  Intestinal cell migration damage induced by enteropathogenic Escherichia coli strains.

Authors:  P A Cavalcante; M M G Prata; P H Q S Medeiros; A V Alves da Silva; J S Quetz; M A V Reyes; T S Rodrigues; A K S Santos; S A Ribeiro; H N Veras; M D Bona; M S M G Amaral; F A P Rodrigues; I F N Lima; A Havt; A A M Lima
Journal:  Braz J Med Biol Res       Date:  2018-07-26       Impact factor: 2.590

8.  The type III secretion system effector EspO of enterohaemorrhagic Escherichia coli inhibits apoptosis through an interaction with HAX-1.

Authors:  Sharanya Chatterjee; Sujinna Lekmeechai; Nicolas Constantinou; Ewa A Grzybowska; Zuzanna Kozik; Jyoti S Choudhary; Cedric N Berger; Gad Frankel; Abigail Clements
Journal:  Cell Microbiol       Date:  2021-06-24       Impact factor: 4.115

9.  Escherichia coli O127 group 4 capsule proteins assemble at the outer membrane.

Authors:  Matthew R Larson; Kassia Biddle; Adam Gorman; Sarah Boutom; Ilan Rosenshine; Mark A Saper
Journal:  PLoS One       Date:  2021-11-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.